Amgen AMGN Vectibix — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amgen's vectibix — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amgen's vectibix — total revenues?
- Amgen (AMGN) reported vectibix — total revenues of $287M in Q1 2026.
- How has Amgen's vectibix — total revenues changed year-over-year?
- Amgen's vectibix — total revenues increased by 7.5% year-over-year, from $267M to $287M.
- What is the long-term trend for Amgen's vectibix — total revenues?
- Over 4 years (2021 to 2025), Amgen's vectibix — total revenues has grown at a 7.7% compound annual growth rate (CAGR), from $873M to $1.18B.
- What does vectibix — total revenues mean?
- This metric represents the total gross sales generated from the global commercialization of a specific oncology therapeutic product line. It reflects the market adoption, pricing power, and competitive positioning of the drug within the colorectal cancer treatment landscape. Revenue growth in this segment is driven by clinical utility, physician prescribing patterns, and the expansion of approved indications.